[Pharmacokinetics of 99mTc-technephore in man]

Area of Science:

• Nuclear Medicine
• Radiopharmacology

Background:

• Assessing the pharmacokinetics of novel radiopharmaceuticals is crucial for their clinical application.
• Understanding drug distribution and clearance is essential for diagnostic imaging efficacy.

Purpose of the Study:

• To evaluate the pharmacokinetics and diagnostic potential of 99mTc-technephore in patients with non-osteogenic neoplasms.
• To determine the biodistribution, blood clearance, and imaging capabilities of 99mTc-technephore.

Main Methods:

• Whole-body radiometry, blood radiometry, and osteoscintigraphy were performed on 43 patients.
• Pharmacokinetic analysis involved measurements at hourly intervals for 4-5 hours post-injection.
• Gamma-chamber and scanner imaging were initiated 2.5-3 hours after administration.

Main Results:

• 99mTc-technephore rapidly redistributed between the skeleton and urinary system within minutes of injection.
• By 3 hours, 59% of the administered dose was in the bladder, with rapid blood clearance (≤6%).
• A high skeleton-to-background ratio (312%) enabled high-quality scintigrams, with sensitivity and specificity comparable to other agents.

Conclusions:

• 99mTc-technephore exhibits favorable pharmacokinetic properties for bone imaging.
• The drug's high differential accumulation in osseous tissue supports its use as an osteotropic agent.
• 99mTc-technephore shows promise for clinical application in diagnosing bone-related conditions.